Oppenheimer on July 24 raised the firm’s price target on Boston Scientific (BSX) to $118 from $110 and kept a Perform rating on the shares. The firm updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Insider Moves: Charles Schwab, Phillips 66, NXP, Corning, Boston Scientific
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Positive Outlook for Boston Scientific Driven by Strong Growth Strategy and Leadership in Key Segments
- Boston Scientific price target raised to $125 from $120 at RBC Capital
- Boston Scientific price target raised to $118 from $110 at Oppenheimer